We explored the treatment of a patient poisoned by the Lepiota brunneoincarnata mushroom, which marked its first record in Argentina. This individual, a 51-year-old male, presented with troubling symptoms such as nausea, vomiting, abdominal pain, and diarrhea, which surfaced 36 hours after ingestion. The quick actions taken, including the administration of a nasogastric tube and activated charcoal, were crucial in the response to this medical emergency.
Activated charcoal is commonly utilized in cases of food poisoning due to its ability to absorb toxins in the gastrointestinal tract, preventing their further absorption into the bloodstream. In this case, the patient's condition was effectively managed with additional treatments such as N-acetylcysteine, phytomenadione, and penicillin G. His recovery allowed him to be discharged after 11 days.
This case emphasizes the significance of both timely identification of the poisonous mushroom and the role of treatment strategies, including activated charcoal. While the effectiveness of activated charcoal is underscored, it’s important to note that it was part of a broader treatment plan and the overall outcomes reflect a combination of therapies working together.
Read More
We investigated activated charcoal (AC) as a potential treatment for foodborne infections, particularly campylobacteriosis. In our study, infected mice treated with AC showed lower levels of harmful bacteria and experienced fewer severe symptoms like diarrhea.
Interestingly, those receiving AC also had less inflammation throughout their bodies. While the results are promising, it’s important to note that this study was conducted in mice, so further research is needed to see how effective AC might be in humans.
Read More
We explored the effects of activated charcoal (AC) as a potential treatment for campylobacteriosis, a foodborne illness caused by the Campylobacter bacteria. In our study, we used microbiota-depleted IL-10 mice to understand how AC might influence the disease's progression. Mice were infected and then treated with either AC or a placebo starting on the second day of their infection.
Our observations showed that the mice receiving AC had significantly lower levels of the harmful bacteria in their intestines. Additionally, these mice experienced fewer clinical symptoms such as diarrhea and weight loss compared to those who received the placebo treatment.
Beyond just improving gut health, AC treatment also appeared to lessen inflammation in the intestines. We noted that this approach not only helped with local symptoms but also reduced inflammation in other parts of the body. Given these findings, activated charcoal demonstrates potential as a safe, non-antibiotic option to treat human campylobacteriosis effectively.
Read More
We explored the potential benefits of activated charcoal for patients suffering from amatoxin poisoning. Through a systematic review of case reports and literature, we analyzed how interrupting the enterohepatic circulation could enhance treatment effectiveness. Our findings indicate that activated charcoal may significantly improve patient outcomes by aiding in the elimination of amatoxin and reducing liver function markers.
However, it’s crucial to note the limitations of the study, such as the risk of publication bias and challenges in measuring amatoxin levels directly.
Read More
We explored whether activated charcoal can effectively reduce the levels of the antibiotic ceftriaxone in human fecal samples. By testing samples from eight patients treated with intravenous ceftriaxone, we found that charcoal did indeed show a significant reduction in ceftriaxone concentration.
At a common treatment dose, the charcoal absorbed nearly half of the antibiotic. Higher charcoal doses improved this effect even more. While our findings suggest that charcoal could help maintain gut health during antibiotic treatment, more research is needed to confirm these effects in real-life conditions.
Read More